enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Meet the Biotech Stock That Has Generated Nvidia-Like ... - AOL

   www.aol.com/finance/meet-biotech-stock-generated...

   Between Oct. 11 and Nov. 8, Bright Minds' stock rallied an incredible 4,220%. Nvidia, by comparison, has generated 2,700% returns, but that's been over a span of five years .

3. Bright Minds Biosciences and Firefly Neuroscience to ...

   lite.aol.com/tech/story/0022/20241021/9258929.htm

   NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial ...

4. Bright Minds' Second-Gen Psychedelic Drugs Ready to Be ... - AOL

   www.aol.com/news/bright-minds-second-gen...

   Bright Minds Biosciences (OTC: BMBIF), a Canadian-based biotechnology company, is developing the next-generation serotonergic drugs to treat various central nervous system (CNS) disorders. Over ...

5. BMB-201 - Wikipedia

   en.wikipedia.org/wiki/BMB-201

   BMB-201 is under development by Bright Minds Biosciences. [ 1 ] [ 2 ] As of October 2024, its highest developmental phase is preclinical research . [ 1 ] [ 2 ] The chemical structure of BMB-201 does not yet appear to have been disclosed.

6. Finance News & Latest Business Headlines - AOL.com

   www.aol.com/finance

   Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.

7. BMB-101 - Wikipedia

   en.wikipedia.org/wiki/BMB-101

   BMB-101 is under development by Bright Minds Biosciences. [1] [2] As of October 2023, it is in phase 2 clinical trials for absence epilepsy and Pitt-Hopkins syndrome, phase 1 clinical trials for Dravet syndrome, and is in preclinical research for binge-eating disorder, Lennox-Gastaut syndrome, and opioid-related disorders.

8. Alan P. Kozikowski - Wikipedia

   en.wikipedia.org/wiki/Alan_P._Kozikowski

   Currently, Kozikowski is working in Bright Minds Biosciences to develop new psychedelic-based compounds to treat mental health disorders and cluster headaches. [10] Kozikowski has been noted for his criticism of current drug discovery programs in psychiatry and potential overmedicalization. [11]

9. Why Emergent BioSciences Stock Plummeted Today - AOL

   www.aol.com/finance/why-emergent-biosciences...

   In return for this, the vaccine maker issued slightly over 1.1 million shares of its common stock to OHA, plus 2.5 million warrants to buy said stock. In the sale, the sellers will divest up to a ...